Document Detail

Effects of intracoronary injection of autologous bone marrow-derived stem cells on natriuretic peptides and inflammatory markers in patients with acute ST-elevation myocardial infarction.
MedLine Citation:
PMID:  20953959     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: Intracoronary administration of autologous bone marrow stem cells (BMC) has been shown to result in a subtle improvement of global left ventricular ejection fraction after ST-elevation myocardial infarction (STEMI), but the overall benefits of BMC therapy are still unclear. We studied the influence of intracoronary injections of BMC on levels of natriuretic peptides and inflammatory mediators, which are well established prognostic biomarkers, in patients with STEMI.
METHODS: In this randomized, double-blind study, consecutive patients with an acute STEMI treated with thrombolysis followed by PCI 2-6 days after STEMI, were randomly assigned to receive either intracoronary BMC or placebo medium into the infarct-related artery. Blood samples were drawn for biochemical determinations.
RESULTS: From baseline to 6 months, there was a significant decrease in the levels of N-terminal probrain natriuretic peptide (NT-proBNP), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) in the whole patient population (P < 0.001 for all). However, no difference was observed between the BMC group (n = 39) and the placebo group (n = 39) in the change of the levels of NT-proANP (median -54 vs. +112 pmol/L), NT-proBNP (-88 vs. -115 pmol/L) or inflammatory markers IL-6 (-3.86 vs. -5.61 pg/mL), hsCRP (-20.29 vs. -22.36 mg/L) and tumor necrosis factor α (-0.12 vs. -0.80 pg/mL) between baseline and 6 months.
CONCLUSION: Intracoronary BMC therapy does not appear to exert any significant effects on the secretion of natriuretic peptides or inflammatory biomarkers in STEMI patients.
Johanna A Miettinen; Kari Ylitalo; Pirjo Hedberg; Kari Kervinen; Matti Niemelä; Marjaana Säily; Pirjo Koistinen; Eeva-Riitta Savolainen; Heikki Ukkonen; Mikko Pietilä; K E Juhani Airaksinen; Juhani Knuuti; Olli Vuolteenaho; Timo H Mäkikallio; Heikki V Huikuri
Related Documents :
16172169 - Tachycardia-induced myocardial ischemia and diastolic dysfunction potentiate secretion ...
16762459 - T4-induced cardiac hypertrophy disrupts cyclic gmp mediated responses to brain natriure...
16720429 - Nt-probnp serum levels reflect severity and extent of ischemia in patients admitted wit...
20953959 - Effects of intracoronary injection of autologous bone marrow-derived stem cells on natr...
10520779 - Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and...
15653109 - Prognostic value of cardiac troponin t in patients with both acute and chronic stable c...
24265259 - The role of pygopus in the differentiation of intracardiac valves in drosophila.
12373049 - Myocardial perfusion abnormalities early (12-24 h) after coronary stenting or balloon a...
204409 - Malignant fibrous histiocytoma and pleomorphic sarcoma in association with medullary bo...
Publication Detail:
Type:  Journal Article     Date:  2010-10-17
Journal Detail:
Title:  Clinical research in cardiology : official journal of the German Cardiac Society     Volume:  100     ISSN:  1861-0692     ISO Abbreviation:  Clin Res Cardiol     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101264123     Medline TA:  Clin Res Cardiol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  317-25     Citation Subset:  IM    
Department of Internal Medicine, Institute of Clinical Medicine, University of Oulu, Kajaanintie 50, P.O. Box 5000, FI-90014, Oulu, Finland,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Radiotransparency of polyvinylpyrrolidone-hydrogel and hydrogel breast implants: a quantitative anal...
Next Document:  Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients.